NCT04554628

Brief Summary

Early prediction of AKI can help to improve patients' outcome through early institution of the appropriate intervention, thus the current study hypothesizes that urine analysis for certain markers may provide an early knowledge about the possibility of oncoming kidney affection secondary to organ and tissue trauma affecting patients admitted to surgical ICU. The current study tries to evaluate the value of urinary markers as early predictors of possible development of AKI in patients admitted to surgical ICU.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Sep 2019

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 14, 2019

Completed
12 months until next milestone

First Submitted

Initial submission to the registry

September 3, 2020

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 3, 2020

Completed
15 days until next milestone

First Posted

Study publicly available on registry

September 18, 2020

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 10, 2020

Completed
Last Updated

March 10, 2021

Status Verified

March 1, 2021

Enrollment Period

12 months

First QC Date

September 3, 2020

Last Update Submit

March 7, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • The ability of estimated urinary markers for prediction of patients susceptible to develop AKI.

    The ability of UNGAL and UKIM1 to early predict acute kidney injury before the serum creatinine rises.

    180 days

Secondary Outcomes (2)

  • The number of patients who developed rise of Serum Creatinine diagnostic of AKI and the extent of AKI severity

    180days

  • The best detector of acute kidney injury

    180 days

Study Arms (2)

Urinary human neutrophil gelatinase-associated lipocalin

ACTIVE COMPARATOR

Urinary human neutrophil gelatinase-associated lipocalin (U-NGAL) measurement

Diagnostic Test: ELISA test in urine

Urinary human kidney injury molecule 1 (U-KIM1)

ACTIVE COMPARATOR

Urinary human kidney injury molecule 1 (U-KIM1) measurement group

Diagnostic Test: ELISA test in urine

Interventions

ELISA test in urineDIAGNOSTIC_TEST

enzyme linked immunosorbent assay technology for detection of UNGAL and UKIM1 in urine in postoperative ICU patients

Also known as: enzyme linked immunosorbent assay technology
Urinary human kidney injury molecule 1 (U-KIM1)Urinary human neutrophil gelatinase-associated lipocalin

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may not qualify if:

  • Patients with manifest kidney disease.
  • Patients had renal surgery
  • Patients maintained on renal replacement therapy
  • Patients had diabetic nephropathy.
  • Patients had liver disease, endocrinopathies.
  • Patients morbid obesity that was defined as body mass index (BMI) \>35 kg/m2 .

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Security Forces Hospital

Riyadh, 00966, Saudi Arabia

Location

MeSH Terms

Conditions

Acute Kidney Injury

Interventions

Urination

Condition Hierarchy (Ancestors)

Renal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

Urinary Tract Physiological PhenomenaReproductive and Urinary Physiological Phenomena

Study Officials

  • Mohammed Abosamak

    Security Forces Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
DIAGNOSTIC
Intervention Model
SEQUENTIAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
lecturer of anesthesia and intensive care

Study Record Dates

First Submitted

September 3, 2020

First Posted

September 18, 2020

Study Start

September 14, 2019

Primary Completion

September 3, 2020

Study Completion

December 10, 2020

Last Updated

March 10, 2021

Record last verified: 2021-03

Data Sharing

IPD Sharing
Will share
Shared Documents
STUDY PROTOCOL

Locations